In the last trading session, 0.13 million Compass Therapeutics Inc (NASDAQ:CMPX) shares changed hands as the company’s beta touched 0.74. With the company’s per share price at $1.50 changed hands at -$0.01 or -0.66% during last session, the market valuation stood at $206.38M. CMPX’s last price was a discount, traded about -56.0% off its 52-week high of $2.34. The share price had its 52-week low at $0.76, which suggests the last value was 49.33% up since then. When we look at Compass Therapeutics Inc’s average trading volume, we note the 10-day average is 0.39 million shares, with the 3-month average coming to 486.68K.
Analysts gave the Compass Therapeutics Inc (CMPX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.38. If we narrow down to specifics, the data shows that 1 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CMPX as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Compass Therapeutics Inc’s EPS for the current quarter is expected to be -0.09.
Compass Therapeutics Inc (NASDAQ:CMPX) trade information
Instantly CMPX was in red as seen at the end of in last trading. With action -1.96%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -3.85%, with the 5-day performance at -1.96% in the red. However, in the 30-day time frame, Compass Therapeutics Inc (NASDAQ:CMPX) is 0.67% up. Looking at the short shares, we see there were 1.45 million shares sold at short interest cover period of 2.66 days.
The consensus price target for the stock as assigned by Wall Street analysts is 5, meaning bulls need an upside of 70.0% from its current market value. According to analyst projections, CMPX’s forecast low is 5 with 5 as the target high. To hit the forecast high, the stock’s price needs a -233.33% plunge from its current level, while the stock would need to soar -233.33% for it to hit the projected low.
Compass Therapeutics Inc (CMPX) estimates and forecasts
Data shows that the Compass Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 41.51% over the past 6 months, a -6.06% in annual growth rate that is considerably lower than the industry average of 16.70%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 12.88%. The 2024 estimates are for Compass Therapeutics Inc earnings to decrease by -6.06%.
CMPX Dividends
Compass Therapeutics Inc is expected to release its next quarterly earnings report in January.
Compass Therapeutics Inc (NASDAQ:CMPX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 12.55% of Compass Therapeutics Inc shares while 69.16% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 79.09%. There are 69.16% institutions holding the Compass Therapeutics Inc stock share, with ORBIMED ADVISORS LLC the top institutional holder. As of 2024-06-30, the company held 16.3701% of the shares, roughly 22.36 million CMPX shares worth $22.36 million.
ADAGE CAPITAL PARTNERS GP, L.L.C. holds the second largest percentage of outstanding shares, with 8.1474% or 11.13 million shares worth $11.13 million as of 2024-06-30.
